Postexposure prophylaxis for HIV following sexual exposure

Current Opinion in HIV and AIDS

Volumn 5, Issue 4, 2010, Pages 322-326

  Barber, Tristan J ^a   Benn, Paul D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral therapy; Guidelines; HIV; Postexposure prophylaxis; Sexual behaviour; Sexual exposure

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ATAZANAVIR; ATORVASTATIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; METHADONE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; SIMVASTATIN; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADD ON THERAPY; ANTIVIRAL RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SUBSTITUTION; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KIDNEY TUBULE DISORDER; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; STEVENS JOHNSON SYNDROME; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; DRUG INTERACTIONS; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS;

EID: 77953618205     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833a5e6c     Document Type: Review

References (32)

1. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183:215-225.
2. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure to HIVinfected blood: clinical and public health implications. N Engl J Med 1997; 337:1485.
3. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24:907-913.
4. Gray R, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153.
5. Vernazza L, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIVinfection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121.
6. Chun TW, Davey RT, Ostrowski M, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000; 6:757-761.
7. Dummond J, Yeh R, Patterson K, et al. First dose and steady-state genital tract pharmacokinetics in HIV-infected women: implications for pre and post exposure prophylaxis. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections; Denver; February 2006; abstract 129.
8. Bryant J, Baxter L, Hird S. Nonoccupational post exposure prophylaxis for HIV: a systematic review. Health Technol Assess 2009; 13:iii, ix-x, 1-60.
9. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation PMPA treatment for prevention of persistent SIV infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
10. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335:1621-1629.
11. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following non occupational post exposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-1513.
12. Benn P, Mercey D, Brink N, et al. Postexposure prophylaxis using a nevirapine based regimen. Lancet 2001; 357:687-688.
13. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral post exposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR 2005; 54:1-20.
14. National guidelines for post exposure prophylaxis after non-occupational exposure to HIV 2007. http://www.ashm.org.au/images/publications/guide lines/2007nationalnpepguidelines2.pdf.
15. Post exposure prophylaxis to prevent HIV infection 2007. http://whqlibdoc. who.int/publications/2007/9789241596374-eng.pdf.
16. Fisher M, Benn P, Evans B, et al. United Kingdom Guideline for the use of postexposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006; 17:1-12.
17. Clinical management and treatment of HIV infected adults in Europe version five 2009. European AIDS Clinical Society. http://www. europeanaidsclinicalsociety. org/guidelinespdf/EACS- EuroGuidelines2009FullVersion.pdf.
18. Winston A, McAllister J, Amin J, et al. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV postexposure prophylaxis. HIV Med 2005; 6:191-197.
19. Garcia-Lerma G, Cong M-E, Zheng Q, et al. Efficacy of intermittent prophylaxis with tenofovir and emtricitabine against rectal SHIV transmission in macaques and relationship to systemic and mucosal drug levels. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; February 2010; abstract 83.
20. Pasticci MB, Bonora S, DI Candilo F, et al. Transitory severe CNS adverse effects after accidental efavirenz overdose during postexposure HIV prophylaxis. J Acquir Immune Defic Syndr 2008; 47:241-247.
21. Kaletra1 Summary of Product Characteristics. Electronic Medicines Compendium; 2007. http://emc.medicines.org.uk/.
22. Diaz-Brito V, Leó n A, Knobel H, et al. An open randomized multicenter clinical trial comparing zidovudine/lamivudine plus lopinavir/ritonavir or plus atazanavir used as postexposure prophylaxis for HIV infection. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; February 2010; abstract 956.
23. HIV drug interactions website. University of Liverpool. http://www.hiv-drugin teractions.org/. [Accessed February 2010]
24. Mayer K, Mimiaga M, Gelman M, et al. Tenofovir DF/emtricitabine/ raltegravir appears safe and well tolerated for nonoccupational postexposure prophylaxis. In: Proceedings of the 5th IASConference on HIV Pathogenesis, Treatment and Prevention; Cape Town; 19-22 July 2009; abstract WEAC104.
25. Clavel C, Mandelbrot L, Marcelin A-G, et al. Raltegravir concentrations in the cervicovaginal compartment exceed the median inhibitory concentration in HIV-1-infected women treated with a raltegravir-containing regimen: DIVA 01 study. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; February 2010; Abstract 608.
26. Brown K, Patterson K, Malone S, et al. Antiretrovirals for prevention: maraviroc exposure in the semen and rectal tissue of healthy male volunteers after single and multiple dosing. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; February 2010; Abstract 85.
27. Mé chai F, Quertainmont Y, Sahali S, et al. Postexposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multiresistant HIV-infected source person. J Med Virol 2008; 80:9-10.
28. UK HIV drug resistance database. http://www.ctu.mrc.ac.uk/pdf/HIV-Res- Report09.pdf. [Accessed February 2010]
29. Pinkerton SD, Martin JN, Roland ME, et al. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18:2065-2073.
30. Guinot D, Ho MT, Poynten IM, et al. Cost-effectiveness of HIV nonoccupational postexposure prophylaxis in Australia. HIV Med 2009; 10:199-208.
31. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behaviour. AIDS 2004; 18:787-792.
32. Poynten IM, Jin F, Limin M, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23:1119-1126.